Executive Profile

Paul J. Hastings Chief Executive Officer, President and Director, OncoMed Pharmaceuticals, Inc.

Age	Total Calculated Compensation	This person is connected to 11 Board Members in 11 different organizations across 10 different industries. See Board Relationships
52	$569,745 As of Fiscal Year 2012

Background

Mr. Paul J. Hastings has been the Chief Executive Officer and President at OncoMed Pharmaceuticals, Inc. since January 2006. Mr. Hastings served as Business Advisor at Valocor Therapeutics, Inc. He joined OncoMed in 2006. He has over 20 years of experience as a biotechnology and pharmaceutical industry executive. He served as the President and Chief Executive Officer of QLT Inc. from February 2002 to September 2005, where he managed the ongoing development and commercialization ... alliance with Novartis of QLT's anti-blindness photodynamic therapy treatment generating approximately $500 million in current annual sales. Mr. Hastings served as the President and Chief Executive Officer of Axys Pharmaceuticals, Inc. from January 2001 to February 15, 2002. He started his career in 1984 at Hoffman La Roche. Mr. Hastings has held various positions of increasing responsibility with notable biotech and pharmaceutical companies. From June 1999 to January 2001, he served as the President of Chiron BioPharmaceuticals, a division of Chiron Corporation where he was responsible for worldwide commercial operations of Chiron's biopharma business. He served as the President and Chief Executive Officer of LXR Biotechnology from August 1998 to 1999. Mr. Hastings held a series of management positions at Genzyme Corporation from 1994 to 1998 and served as the President of Genzyme Therapeutics Worldwide from January 1997 to July 1998. He had been responsible for Genzyme's largest and most profitable division marketing enzyme replacement therapy for rare genetic diseases, with additional responsibilities in product development and corporate collaborations. He served as the President of Genzyme Therapeutics, Europe from January 1996 to January 1997; Vice President, General Manager, Genzyme Therapeutics, Europe from April 1995 to January 1996; and Vice President, Global Marketing, Genzyme Therapeutics from August 1994 to April 1995. From 1988 to 1994, Mr. Hastings held positions of increasing responsibility at Synergen, in Boulder, CO, including Vice-President, Marketing and Sales of Synergen Inc. and Vice-President, Marketing and Sales and European General Manager of Synergen Europe Inc. From 1984 to 1989, he was with Hoffmann-La Roche, Nutley, NJ, in marketing and sales management positions and served as Senior Product Manager of Hoffman La Roche from 1987 to 1989. He serves as the Chairman of Onyx Therapeutics, Inc, BayBio and Bay Area Biosciences Association. Mr. Hastings was Chairman of the Board of Proteolix. He serves as Chairman of the Emerging Companies Section of the Biotechnology Industry Organization. He served as the Vice Chair of the Emerging Companies Section of the Biotechnology Industry Association (BIO). He serves as a Director of Biotechnology Industry Association. He serves as a Director and Emerging Companies Section Vice Chairman of Biotechnology Industry Organization. He has been a Director at Pacira Pharmaceuticals Inc. since June 2011 and California Healthcare Institute since April 2010. Mr. Hastings serves as a Director of several private organizations, including B.C.'s Leading Edge Endowment Fund, Arriva Pharmaceuticals, Inc., the B.C. Biotech Association and Vancouver's St. Paul's Hospital. He has been Director of Relypsa, Inc since January 02, 2013. He has been a Director for OncoMed Pharmaceuticals, Inc. since January, 2006. He served as Director of ViaCell Inc. since November 2000 and its Member of Supervisory Board since October 23, 2003. He served as a Director of Cerimon Pharmaceuticals, Inc. He serves as a Director of AXYS Pharmaceuticals, Inc He served as a Director of QLT Inc., from February 2002 to September 2005. He served as a Director of LXR Biotechnology Inc., since 1998. Mr. Hastings holds a Bachelor of Science degree in Pharmacy from the University of Rhode Island.

Corporate Headquarters 800 Chesapeake Drive Redwood City, California 94063 United States Phone: 650-995-8200 Fax: 650-995-8600 Board Members Memberships Director AXYS Pharmaceuticals, Inc Director Arriva Pharmaceuticals, Inc. Director Biotechnology Industry Organization Chairman Onyx Therapeutics, Inc. Chairman BayBio Director Cerimon Pharmaceuticals, Inc. 1998-N/A Former Chief Executive Officer, President and Director LXR Biotechnology Inc. 2000-Present Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee ViaCell, Inc. 2002-2005 Former Chief Executive Officer, President and Director QLT Inc. 2006-Present Chief Executive Officer, President and Director OncoMed Pharmaceuticals, Inc. 2010-Present Director California Healthcare Institute 2011-Present Director, Chairman of Compensation Committee, Member of Audit Committee and Member of Nominating & Corporate Governance Committee Pacira Pharmaceuticals, Inc. 2013-Present Director Relypsa, Inc. Education BS University Of Rhode Island Other Affiliations AXYS Pharmaceuticals, Inc Pacira Pharmaceuticals, Inc. ViaCell, Inc. Chiron, Corp. QLT Inc. TOLMAR Therapeutics, Inc. LXR Biotechnology Inc. California Healthcare Institute Arriva Pharmaceuticals, Inc. University Of Rhode Island Biotechnology Industry Organization Onyx Therapeutics, Inc. BayBio Cerimon Pharmaceuticals, Inc. Relypsa, Inc. Valocor Therapeutics, Inc.

Annual Compensation Salary $438,265 Total Annual Compensation $438,265 Stocks Options Exercisable Options $2,806,652 Total Number of Options $2,806,652 Total Compensation Total Annual Cash Compensation $569,745 Total Short Term Compensation $438,265 Total Calculated Compensation $569,745

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.